



# SPAFID CONNECT

Informazione Regolamentata n. 0472-2-2019	Data/Ora Ricezione 09 Gennaio 2019 10:08:59	MTA - Star
---	---	------------

Societa' : BB BIOTECH  
Identificativo : 112699  
Informazione  
Regolamentata  
Nome utilizzatore : BIOTECHNSS01 - Alderuccio  
Tipologia : REGEM  
Data/Ora Ricezione : 09 Gennaio 2019 10:08:59  
Data/Ora Inizio : 09 Gennaio 2019 10:09:00  
Diffusione presunta  
Oggetto : Corporate events calendar 2019

*Testo del comunicato*

Vedi allegato.



**Press Release, January 9, 2019**

## **Corporate events calendar – 2019**

18/01/2019	Portfolio as of December 31, 2018
15/02/2019	Annual Report 2018
21/03/2019	Annual General Meeting <i>Park Casino, Steigstrasse 26, 8200 Schaffhausen h. 3 pm</i>
20-21/03/2019	STAR Conference 2019 - Milan
26/04/2019	Interim Report as of March 31, 2019
19/07/2019	Interim Report as of June 30, 2019
18/10/2019	Interim Report as of September 30, 2019

The dates of the meetings with the financial community will be made public later on.

### **For further information:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, [tch@bellevue.ch](mailto:tch@bellevue.ch)  
[www.bbbiotech.com](http://www.bbbiotech.com)

### **Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.5 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-2

Numero di Pagine: 3